The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein

The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein

Vemurafenib (PLX4032), small-molecule inhibitor of mutated BRAFV600E protein, has emerged as a potent anti-cancer agent against metastatic melanoma harboring BRAFV600E mutation. Unfortunately, the effect of PLX4032 in the treatment of metastatic BRAF mutated colorectal cancer (CRC) is less potent du...

Full description

Bibliographic Details
Main Authors: Petra Grbčić, Thomas O. Eichmann, Sandra Kraljević Pavelić, Mirela Sedić
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:International Journal of Molecular Sciences
Subjects:
colon cancer
BRAFV600E
PLX4032
vemurafenib
sphingolipids
sphingosine-1-phosphate
Online Access:https://www.mdpi.com/1422-0067/22/19/10767

Internet

https://www.mdpi.com/1422-0067/22/19/10767

Similar Items